Key result
SRSF1 overexpression improved cardiac function and reduced infarct size in acute myocardial infarction mice by regulating Bcl2L12 alternative splicing to suppress cardiomyocyte apoptosis.
Why the study?
The function and mechanism of serine/arginine splicing factor 1 (SRSF1) in cardiovascular diseases remain unclear.
Does SRSF1 overexpression reduce cardiomyocyte apoptosis and infarct size in a mouse model of acute myocardial infarction?
Population
AMI mice and cardiomyocytes
Comparison
SRSF1 overexpression vs controls
Design
In vivo animal and in vitro cellular mechanistic study
Authors
Loading...
Hypothesis-generating for SRSF1 in murine AMI; leaves open translation to human ischemic disease.
Does SRSF1 overexpression reduce cardiomyocyte apoptosis and infarct size in a mouse model of acute myocardial infarction?
SRSF1 overexpression attenuates cardiomyocyte apoptosis and improves cardiac function post-myocardial infarction by regulating Bcl2L12 alternative splicing, highlighting a potential therapeutic target for ischemic heart disease.
Xie et al. (2024) studied Acute myocardial infarction. SRSF1 overexpression (AAV9-SRSF1) vs. Empty AAV9 vector was evaluated on Cardiomyocyte apoptosis and cardiac function. SRSF1 overexpression improved cardiac function and reduced infarct size in acute myocardial infarction mice by regulating Bcl2L12 alternative splicing to suppress cardiomyocyte apoptosis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: